FIELD: medicine, pharmaceutics.
SUBSTANCE: what is presented is using one or more lactic acid oligomers as an active ingredient for preparing a drug for prevention and/or treatment of gynaecological infections wherein one or more lactic acid oligomers have formula 
(I) wherein n represents an integer from 2 to 50 and a respective pharmaceutical composition. What is shown is an immediate and prolonged effect (a little more than 12 hours) on the vaginal pH value.
EFFECT: providing an acid medium in the therapy of gynaecological infections (such as bacterial vaginosis, non-specific colpitis, senile colpitis, cervicitis and urethritis, a mycotic infection, such as candidiasis - Candida albicans, cryptococcosis, actinomycosis, or a viral infection such as human immunodeficiency virus (HIV), herpex simplex virus (HSV), human papilloma virus (HPV)) allows less frequent introduction of the formulations as compared to currently known ones.
22 cl, 14 dwg, 18 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITIONS COMPRISING OLIGOMERIC LACTIC ACID | 2013 |
|
RU2627470C2 |
| VAGINAL GEL | 2021 |
|
RU2834988C1 |
| EFFERVESCENT COMPOSITION IN SOLID FORM FOR USE IN VAGINAL APPLICATIONS FOR TREATING VAGINAL INFECTIONS | 2012 |
|
RU2587717C2 |
| FOAMING COMPOSITIONS AND METHODS FOR DELIVERING ACTIVE AGENT INTO BODY CAVITY | 2015 |
|
RU2710019C2 |
| FOAMING COMPOSITIONS FOR DELIVERY OF ACTIVE AGENT TO BODY CAVITY | 2018 |
|
RU2773520C2 |
| VIRUCIDAL, BACTERICIDAL AND SPERMATOCIDAL SUPPOSITORIUM | 1994 |
|
RU2147431C1 |
| AGENT FOR INTRAVAGINAL DELIVERY OF ACTIVE COMPONENT, METHOD OF PRODUCTION AND USE OF THE MEDICINAL PRODUCT | 2022 |
|
RU2806114C2 |
| PHARMACEUTICAL AGENT FOR INTRAVAGINAL ADMINISTRATION, METHOD FOR ITS PREPARATION AND USE | 2023 |
|
RU2830742C1 |
| USE OF TOTAROL AND PHARMACEUTICAL COMPOSITION CONTAINING TOTAROL | 2018 |
|
RU2812223C2 |
| PHARMACEUTICAL COMPOSITIONS WITH A SELECTED DURATION OF RELEASE | 2017 |
|
RU2756514C1 |
